Autopsy report · NCT02605044
Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
Cause of deathFunding or business
“Sponsor decision based on portfolio prioritization”
Life of this trial
- Registered 1 year 10 months after it had already started.
- Ran for about 3 years 11 months before it stopped.
- 123 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- AB Science
- Sponsor type
- Industry
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Masitinib (AB1010); FOLFIRI
- Participants
- 123
- Sites
- 3
- Countries
- France, Singapore, United Kingdom
Trials that died the same way
- 99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis
“Sponsor Decision based on strategic considerations” - Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis
“Sponsor decision due to strategic considerations” - Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant
“Strategic sponsor decision” - A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers
“Sponsor decision based on strategic re-alignment” - Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness
“Strategic decision of Sponsor”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.